In summary, oxylipin profiling suggests that systemic administration of CDNF after ischemic stroke blocks the production of oxylipins derived by all biosynthesis pathways including COX, LOX, and CYP450s matching with reduced cPLA2 activity. The gene discussed is LOX; the disease is ischemic stroke.